search
Back to results

Exercise Interventions in Post-acute Sequelae of Covid-19

Primary Purpose

COVID-19

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Exercise
Sponsored by
University of Virginia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for COVID-19

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: 18-50 years of age Diagnosed with Post Acute Sequelae of COVID-19 Physician clearance to undergo exercise training (see section titled cardiorespiratory fitness testing for details; page 6) Complete COVID-19 vaccination status Exclusion Criteria: Unstable angina or myocardial infarction in the past 4 weeks Uncompensated heart failure NYHA class IV symptoms Complex ventricular arrhythmias Musculoskeletal contraindications to stationary bicycling exercise Symptomatic severe aortic stenosis Acute pulmonary embolus Acute myocarditis Uncontrolled Hypertension as defined as systolic blood pressure > 180 mm Hg or diastolic blood pressure > 120 mm Hg Medication non-compliance Pregnant women-self reported COPD GOLD stage D Malignancy currently actively being treated Uncontrolled Asthma Uncompensated Cirrhosis of the Liver Chronic Kidney disease requiring dialysis therapy Symptomatic Anemia Hemoglobin <7g/dL Poorly controlled diabetes or A1c>9% BMI >35kg/m2 Pulmonary Hypertension stage IV Any condition requiring supplemental oxygen Multiple Sclerosis

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    Exercise

    Control

    Arm Description

    Patients will perform 5 days of supervised stationary cycling exercise (with EKG telemetry) per week over a period of 4 weeks. Training heart rates will be determined based on the pre-testing VO2peak and peak heart rate (PHR). Of the 5 sessions, 3 will be HIIT sessions and 2 will be MOD sessions. Subjects exercising on the HIIT day will start with eight intervals of 2-min duration at 80-85% of PHR, separated by 2 min of recovery at 50% of PHR, progressing to four, 4-min intervals at 90-95% PHR, separated by 3 min at 50% PHR by the end of week 2. Subjects exercising on the MOD days will perform uninterrupted for 40 minutes duration at 60-65% of PHR progressing to 40 minutes duration at 70-75% of PHR by the end of week 2. Each training session will begin with a 10-min warm-up at 50% PHR and end with a 5-min cool down at 50% PHR. Exercise progression may have to be modified according to individual subject exercise tolerance.

    The control protocol will include a combination of light stretching and controlled breathing.

    Outcomes

    Primary Outcome Measures

    VO2peak
    Change in VO2peak (L/min) measured pre- and post-intervention
    Left ventricular strain
    Global longitudinal strain and global circumferential strain measured pre- and post-intervention
    Left ventricular diastolic function
    Diastolic dysfunction grade measured pre- and post-intervention

    Secondary Outcome Measures

    Forced expiratory volume in one second (FEV1)
    FEV1 measured via spirometry pre- and post-intervention
    Forced vital capacity (FVC)
    FVC measured via spirometry pre- and post-intervention
    Post COVID-19 Functional Status scale
    Measures subjects functional limitations due to COVID-19 and will be measured via pre- and post-intervention
    Symptom Burden Questionnaire for Long Covid (SBQ-LC)
    Burden of symptoms will be via the SBQ-LC measured pre- and post-intervention
    International Physical Activity Questionnaire (IPAQ)
    Physical activity levels will be assessed via IPAQ measured pre- and post-intervention
    NTproBNP
    Assess changes in NTproBNP (pg/ml) as a biomarker of myocardial strain at pre- and post-intervention
    C-reactive protein (CRP)
    C-reactive protein (mg/dl) will be used as a biomarker for inflammation to be measured pre- and post-intervention
    Lipids
    A lipid panel will be performed to measure total cholesterol, triglycerides, high-density lipoproteins, and low-density lipoprotein (mg/dl) to assess changes in cardiometabolic health pre- and post-intervention
    Fasting glucose
    Fasting blood glucose levels (mg/dl) will be tested to assess changes in cardiometabolic health pre- and post-intervention
    Insulin
    Fasting insulin levels (U/ml) will be tested to assess changes in cardiometabolic health pre- and post-intervention
    Erythrocyte sedimentation rate (ESR)
    ESR will be measured to assess inflammation pre- and post-intervention
    IL-1
    Inflammation will be measured via IL-1 pre- and post-intervention
    IL-6
    Inflammation will be measured via IL-6 pre- and post-intervention
    TNF-a
    Inflammation will be measured via TNF-a pre- and post-intervention
    Fibrinogen
    Fibrinogen will be measured pre- and post-intervention to measure clotting
    D-dimer
    D-dimer will be measured pre- and post-intervention to measure clotting

    Full Information

    First Posted
    September 29, 2023
    Last Updated
    October 3, 2023
    Sponsor
    University of Virginia
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT06065033
    Brief Title
    Exercise Interventions in Post-acute Sequelae of Covid-19
    Official Title
    Exercise as a Therapeutic for Those Diagnosed With Post-acute Sequelae of Covid-19
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    October 2023 (Anticipated)
    Primary Completion Date
    October 2024 (Anticipated)
    Study Completion Date
    October 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Virginia

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The COVID-19 pandemic severely impacted the medical system both directly but also through incomplete recovery from the virus in the form of post-acute sequelae of COVID-19 (PASC). PASC affects at least 9.6 million individuals as of May 2022 and continues to affect many more. PASC is a multisystem disorder often presenting with mental fog, dyspnea on exertion, and fatigue among other symptoms. The etiology of PASC is uncertain but theories include direct cytotoxicity, dysregulated immune responses, endotheliitis associated with microthrombi, eNOS uncoupling, and myocardial fibrosis with impaired ventricular compliance. To date, there are no established treatments. Exercise has the potential as a therapeutic option to improve VO2peak and improve each of the aforementioned underlying etiologies. The investigators plan to examine the effect of High-Intensity Interval Training (HIIT) and Moderate intensity exercise training (MOD) on the symptoms and exercise tolerance of patients with PASC. The investigators approach will consist of a randomized, blinded, 2-arm, parallel-group design. Enrolled subjects will be randomly assigned to one of two groups in a 1:1 allocation ratio. All groups will undergo a 4-week intervention of 3 days of HIIT per week and 2 days of MOD per week or control of light stretching and controlled breathing. Subjects will be assessed before and after the 4-week intervention to examine the extent to which 4 weeks of the HIIT and MOD combination improves VO2peak and left ventricular diastolic function, global longitudinal strain (GLS), and global circumferential strain (GCS). Further, the investigators will explore changes in markers such as heart rate, heart rhythm, blood pressure, quality of life, exercise tolerance, and PASC symptoms as well as blood/serum markers.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    COVID-19

    7. Study Design

    Primary Purpose
    Supportive Care
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    Our approach will consist of a randomized, blinded, 2-arm, parallel-group design
    Masking
    Outcomes Assessor
    Masking Description
    Outcome assessors will be blinded to subject allocation
    Allocation
    Randomized
    Enrollment
    28 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Exercise
    Arm Type
    Experimental
    Arm Description
    Patients will perform 5 days of supervised stationary cycling exercise (with EKG telemetry) per week over a period of 4 weeks. Training heart rates will be determined based on the pre-testing VO2peak and peak heart rate (PHR). Of the 5 sessions, 3 will be HIIT sessions and 2 will be MOD sessions. Subjects exercising on the HIIT day will start with eight intervals of 2-min duration at 80-85% of PHR, separated by 2 min of recovery at 50% of PHR, progressing to four, 4-min intervals at 90-95% PHR, separated by 3 min at 50% PHR by the end of week 2. Subjects exercising on the MOD days will perform uninterrupted for 40 minutes duration at 60-65% of PHR progressing to 40 minutes duration at 70-75% of PHR by the end of week 2. Each training session will begin with a 10-min warm-up at 50% PHR and end with a 5-min cool down at 50% PHR. Exercise progression may have to be modified according to individual subject exercise tolerance.
    Arm Title
    Control
    Arm Type
    No Intervention
    Arm Description
    The control protocol will include a combination of light stretching and controlled breathing.
    Intervention Type
    Behavioral
    Intervention Name(s)
    Exercise
    Intervention Description
    Patients will perform 5 days of supervised stationary cycling exercise (with EKG telemetry) per week over a period of 4 weeks. Training heart rates will be determined based on the pre-testing VO2peak and peak heart rate (PHR). Of the 5 sessions, 3 will be HIIT sessions and 2 will be MOD sessions. Subjects exercising on the HIIT day will start with eight intervals of 2-min duration at 80-85% of PHR, separated by 2 min of recovery at 50% of PHR, progressing to four, 4-min intervals at 90-95% PHR, separated by 3 min at 50% PHR by the end of week 2. Subjects exercising on the MOD days will perform uninterrupted for 40 minutes duration at 60-65% of PHR progressing to 40 minutes duration at 70-75% of PHR by the end of week 2. Each training session will begin with a 10-min warm-up at 50% PHR and end with a 5-min cool down at 50% PHR. Exercise progression may have to be modified according to individual subject exercise tolerance.
    Primary Outcome Measure Information:
    Title
    VO2peak
    Description
    Change in VO2peak (L/min) measured pre- and post-intervention
    Time Frame
    4 weeks
    Title
    Left ventricular strain
    Description
    Global longitudinal strain and global circumferential strain measured pre- and post-intervention
    Time Frame
    4 weeks
    Title
    Left ventricular diastolic function
    Description
    Diastolic dysfunction grade measured pre- and post-intervention
    Time Frame
    4 weeks
    Secondary Outcome Measure Information:
    Title
    Forced expiratory volume in one second (FEV1)
    Description
    FEV1 measured via spirometry pre- and post-intervention
    Time Frame
    4 weeks
    Title
    Forced vital capacity (FVC)
    Description
    FVC measured via spirometry pre- and post-intervention
    Time Frame
    4 weeks
    Title
    Post COVID-19 Functional Status scale
    Description
    Measures subjects functional limitations due to COVID-19 and will be measured via pre- and post-intervention
    Time Frame
    4 weeks
    Title
    Symptom Burden Questionnaire for Long Covid (SBQ-LC)
    Description
    Burden of symptoms will be via the SBQ-LC measured pre- and post-intervention
    Time Frame
    4 weeks
    Title
    International Physical Activity Questionnaire (IPAQ)
    Description
    Physical activity levels will be assessed via IPAQ measured pre- and post-intervention
    Time Frame
    4 weeks
    Title
    NTproBNP
    Description
    Assess changes in NTproBNP (pg/ml) as a biomarker of myocardial strain at pre- and post-intervention
    Time Frame
    4 weeks
    Title
    C-reactive protein (CRP)
    Description
    C-reactive protein (mg/dl) will be used as a biomarker for inflammation to be measured pre- and post-intervention
    Time Frame
    4 weeks
    Title
    Lipids
    Description
    A lipid panel will be performed to measure total cholesterol, triglycerides, high-density lipoproteins, and low-density lipoprotein (mg/dl) to assess changes in cardiometabolic health pre- and post-intervention
    Time Frame
    4 weeks
    Title
    Fasting glucose
    Description
    Fasting blood glucose levels (mg/dl) will be tested to assess changes in cardiometabolic health pre- and post-intervention
    Time Frame
    4 weeks
    Title
    Insulin
    Description
    Fasting insulin levels (U/ml) will be tested to assess changes in cardiometabolic health pre- and post-intervention
    Time Frame
    4 weeks
    Title
    Erythrocyte sedimentation rate (ESR)
    Description
    ESR will be measured to assess inflammation pre- and post-intervention
    Time Frame
    4 weeks
    Title
    IL-1
    Description
    Inflammation will be measured via IL-1 pre- and post-intervention
    Time Frame
    4 weeks
    Title
    IL-6
    Description
    Inflammation will be measured via IL-6 pre- and post-intervention
    Time Frame
    4 weeks
    Title
    TNF-a
    Description
    Inflammation will be measured via TNF-a pre- and post-intervention
    Time Frame
    4 weeks
    Title
    Fibrinogen
    Description
    Fibrinogen will be measured pre- and post-intervention to measure clotting
    Time Frame
    4 weeks
    Title
    D-dimer
    Description
    D-dimer will be measured pre- and post-intervention to measure clotting
    Time Frame
    4 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    50 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: 18-50 years of age Diagnosed with Post Acute Sequelae of COVID-19 Physician clearance to undergo exercise training (see section titled cardiorespiratory fitness testing for details; page 6) Complete COVID-19 vaccination status Exclusion Criteria: Unstable angina or myocardial infarction in the past 4 weeks Uncompensated heart failure NYHA class IV symptoms Complex ventricular arrhythmias Musculoskeletal contraindications to stationary bicycling exercise Symptomatic severe aortic stenosis Acute pulmonary embolus Acute myocarditis Uncontrolled Hypertension as defined as systolic blood pressure > 180 mm Hg or diastolic blood pressure > 120 mm Hg Medication non-compliance Pregnant women-self reported COPD GOLD stage D Malignancy currently actively being treated Uncontrolled Asthma Uncompensated Cirrhosis of the Liver Chronic Kidney disease requiring dialysis therapy Symptomatic Anemia Hemoglobin <7g/dL Poorly controlled diabetes or A1c>9% BMI >35kg/m2 Pulmonary Hypertension stage IV Any condition requiring supplemental oxygen Multiple Sclerosis
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Siddhartha S Angadi, PhD
    Phone
    434-243-7466
    Email
    ssa2w@virginia.edu
    First Name & Middle Initial & Last Name or Official Title & Degree
    Nathan Weeldreyer, MS
    Phone
    434-243-8677
    Email
    nw8ky@virginia.edu
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Siddhartha S Angadi, PhD
    Organizational Affiliation
    University of Virginia
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Exercise Interventions in Post-acute Sequelae of Covid-19

    We'll reach out to this number within 24 hrs